Development and Testing of Adolescent Twelve-Step Facilitation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01449981|
Recruitment Status : Completed
First Posted : October 10, 2011
Last Update Posted : September 13, 2016
|Condition or disease||Intervention/treatment||Phase|
|Alcohol Abuse Alcohol Dependence Drug Abuse Drug Dependence||Behavioral: Integrated Twelve-Step Facilitation Behavioral: Cognitive Behavioral Therapy||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||59 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Development and Testing of Adolescent Twelve-Step Facilitation|
|Study Start Date :||October 2011|
|Actual Primary Completion Date :||March 2015|
|Actual Study Completion Date :||January 2016|
|Experimental: Integrated Twelve-Step Facilitation||
Behavioral: Integrated Twelve-Step Facilitation
The iTSF condition will include review of treatment goals and overall review of progress, coping skills, real life practices, emotions/mood management, how to make changes in one's social network and discussions about how 12-step meetings can be helpful in one's recovery efforts. In addition, speakers from 12-step fellowships such as Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) will be invited to share their experiences and discuss myths and facts related to attendance at 12-step meetings as well as answer any questions participants have about these fellowships.
Other Name: iTSF
|Experimental: Cognitive Behavioral Therapy||
Behavioral: Cognitive Behavioral Therapy
The CBT condition will include review of progress, coping skills, group exercises, real life practice, and emotions/mood management.
Other Name: CBT
- Percent Days Abstinent (PDA) [ Time Frame: Up to 9 months ]Given the goals of both treatments will be abstinence, the main outcome analyses and effect size estimates will be based upon biochemically verified 90 day point-prevalence of PDA. These will be captured using Form-90 (Miller & Del Boca, 1994) which will be used to examine substance use (including number of days used and first and last dates of use within the time period), as well as other treatment experiences in the past 90 days.
- Treatment Acceptability [ Time Frame: Up to 3 months ]Participants will also complete weekly treatment feedback measures to inform the treatment manual.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01449981
|United States, Massachusetts|
|Center for Addiction Medicine 60 Staniford Street|
|Boston, Massachusetts, United States, 02114|
|Principal Investigator:||John F. Kelly, Ph.D.||Massachusetts General Hospital|